Compare VTR & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTR | KVUE |
|---|---|---|
| Founded | 1983 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Specialty Chemicals |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1B | 34.9B |
| IPO Year | 2005 | 2023 |
| Metric | VTR | KVUE |
|---|---|---|
| Price | $87.68 | $17.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $84.77 | $19.73 |
| AVG Volume (30 Days) | 2.2M | ★ 27.0M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | 2.37% | ★ 4.64% |
| EPS Growth | ★ 184.21 | 40.74 |
| EPS | 0.54 | ★ 0.76 |
| Revenue | $5,833,980,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $12.42 | $4.80 |
| Revenue Next Year | $8.32 | $2.52 |
| P/E Ratio | $162.48 | ★ $23.58 |
| Revenue Growth | ★ 18.47 | N/A |
| 52 Week Low | $60.15 | $14.02 |
| 52 Week High | $88.23 | $25.17 |
| Indicator | VTR | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 45.07 |
| Support Level | $66.18 | $17.14 |
| Resistance Level | N/A | $19.07 |
| Average True Range (ATR) | 1.41 | 0.30 |
| MACD | -0.12 | -0.14 |
| Stochastic Oscillator | 90.53 | 26.10 |
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.